论文部分内容阅读
目的比较缬沙坦和福辛普利治疗缺血性心肌病(ICM)心衰的疗效及对血尿酸的影响。方法60例ICM患者分为2组:缬沙坦组予缬沙坦80 mg/d,福辛普利组予福辛普利10 mg/d。治疗前与治疗后12周用超声心动图分别测量左室射血分数(LVEF),左室短轴分数(LVFS),每博输出量(SV),心排量(CO),心脏指数(C I)及血尿酸浓度。结果治疗12周后,2组心功能较治疗前明显改善(P<0.01),但2组之间比较差异无统计学意义(P>0.05),缬沙坦组治疗前、后血尿酸分别为(612±198)mmol/L和(420±152)mmol/L,2组比较差异有统计学意义(P<0.05),福辛普利组治疗前、后血尿酸分别是(590±199)mmol/L和(582±196)mmol/L,差异无统计学意义(P>0.05)。结论缬沙坦和福辛利改善ICM的心功能作用相似,缬沙坦可降低血尿酸水平。
Objective To compare the effects of valsartan and fosinopril on heart failure in patients with ischemic cardiomyopathy (ICM) and its effect on serum uric acid. Methods Sixty ICM patients were divided into two groups: valsartan with valsartan 80 mg / d and fosinopril with fosinopril 10 mg / d. Echocardiography was used to measure left ventricular ejection fraction (LVEF), left ventricular fractional short axis (LVFS), output per patient (SV), cardiac output (CO), cardiac index ) And serum uric acid concentration. Results After 12 weeks of treatment, heart function of the two groups was significantly improved (P <0.01), but there was no significant difference between the two groups (P> 0.05). Serum and uric acid in the valsartan group before and after treatment were (612 ± 198) mmol / L and (420 ± 152) mmol / L respectively. There was significant difference between the two groups (P <0.05). The serum uric acid levels in the fosinopril group before and after treatment were (590 ± 199) mmol / L and (582 ± 196) mmol / L, the difference was not statistically significant (P> 0.05). Conclusions Valsartan and Fosinil can improve cardiac function of ICM. Valsartan can lower serum uric acid.